Loteprednol etabonate
SAFETY AND EFFICACY OF LOTEPREDNOL ETABONATE 0 5% VERSUS PREDNISOLONE ACETATE 1% FOR THE TREATMENT OF PAIN AND INFLAMMATION AFTER CATARACT SURGERY A PROSPECTIVE OBSERVATIONAL STUDY
... According to this study different ranges of pain scale in patients with Prednisolone Acetate after cataract surgery were analyzed. Out of 8 patients who have been administered with PA, the patients with SK+ showing pain ...
11
<p>Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery</p>
... Loteprednol etabonate (LE) is a topical corticosteroid approved by the FDA for postoperative in fl ammation and pain following ocular surgery and is marketed as a suspen- sion, ointment, a gel formulation at ...
10
A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
... Background: While loteprednol etabonate (LE) suspension 0.5% is approved for the treatment of postoperative ocular inflammation, there have been no reported studies of its use in glauc[r] ...
11
A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery
... Results: Data were collected on 189 LASIK eyes (96 patients) and 209 PRK eyes (108 patients). Mean (standard deviation [SD]) years of age at surgery was 36.0 (11.7) and 33.9 (11.3) in LASIK and PRK patients. LE gel was ...
9
An update on the surgical management of pterygium and the role of loteprednol etabonate ointment
... steroid loteprednol etabon- ate, which has been shown to have a lower risk of elevated intraocular pressure than have the other topical ocular ...outcomes. Loteprednol etabonate, especially the ...
14
Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
... Abstract: The eye has protective barriers (ie, the conjunctival and corneal membranes) and defense mechanisms (ie, reflex tearing, blinking, lacrimal drainage) which present challenges to topical drug delivery. Topical ...
14
FORMULATION AND EVALUATION OF SOLUBILITY ENHANCED IN SITU GELLING EYE DROPS OF LOTEPREDNOL ETABONATE
... In situ forming gels are formulations that are applied as solutions or suspensions and undergo gelation due to physicochemical changes in the eye and are triggered by increased temperature, pH, or ionic strength. ...
8
Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper
... Methods: PRK was performed on 261 eyes of 132 participants. Patients were randomized to a postoperative corticosteroid regimen of either loteprednol etabonate 0.5% gel (lotepre- dnol) or prednisolone 1% ...
6
<p>Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies</p>
... The clinical development program designed to evaluate the safety and ef fi cacy of LE (submicron) gel 0.38% included two similarly designed, Phase III, randomized, vehicle-controlled tria[r] ...
12
Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial
... Results from secondary end points, including complete resolution of ACC at days 15 and 18, grade 0 pain at days 3, 15 and 18, and anterior chamber flare at all visits were sup[r] ...
12
Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
... Drug concentrations for the branded and generic prednisolone acetate suspensions following expression from unshaken bottles were highly variable (overall relative SDs of 16.[r] ...
7
Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
... Approximately 400 patients were planned to be enrolled in each study (200 patients per treatment group), to yield approximately 180 patients per treatment group completing the [r] ...
10
Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery
... rejections. Loteprednol etabonate (LE) had been introduced, and 6%–12% of respondents solely used LE when continuing steroids longer than 6 months after ...
9
Click here to download PDF version of the article !
... Methods: The effect of the topical NSAID, flurbiprofen sodium 0.03%, was studied and compared with that of the topical steroid – Loteprednol etabonate 0.5% suspension (as eye drops) in a prospective, open ...
5
Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus
... remogliflozin etabonate with or without metformin greatly increased urine glucose excretion and the percent of filtered glucose excreted in the ...remogliflozin etabonate and sustained while on treat- ...
11
GLIFLOZIN A NEW CLASS FOR TYPE II DIABETES MELLITUS: AN OVERVIEW
... Remogliflozin etabonate having water solubility ...Remogliflozin etabonate significantly increases urinary glucose excretion and reduces plasma glucose concentration 29 ...
8
First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus
... One of these subjects had normal beta-2 microglobulin values at 1 and 4 days after dosing with 500 mg remogliflozin etabonate. However, 11 days after dosing, this subject returned to the clinic for the Day -2 ...
11
Use of loteprednol for routine prophylaxis after photorefractive keratectomy
... Institutional review board approval was obtained and a retrospective chart review of patients who received photorefractive keratectomy surgery at the Moran Eye Center between January 2005 and May 2010 was performed. ...
7